Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis 2026

Regeneron is a leading biopharmaceutical company known for breakthrough medicines in ophthalmology, immunology/inflammation, and oncology. Eylea (aflibercept) treats wet age-related macular degeneration (AMD) and diabetic macular edema and was the world's top-selling ophthalmology drug. Dupixent (dupilumab), a biologic for Type 2 inflammatory conditions (atopic dermatitis, asthma, COPD), has grown to be one of the best-selling drugs globally. Regeneron uses its proprietary Velocimmune technology to develop fully human antibodies more efficiently.

This chart shows how Regeneron Pharmaceuticals's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Regeneron Pharmaceuticals Inc. trades at a trailing P/E of 19.65x, generates $3.07B in free cash flow, runs a debt/equity ratio of 8.54, and converts shareholder equity into profit at a 14.0% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

23 analysts covering Regeneron Pharmaceuticals Inc. currently lean toward a Buy rating, with a mean 12-month price target of $840.43 (+7.1% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

We use 1 valuation model to estimate REGN's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

REGN is currently in a short-term uptrend, trading above its 50-day average of $720.40 and above its 200-day average of $729.31. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

REGN's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.